Bicycle Therapeutics plc (NASDAQ:BCYC) Shares Sold by Horizon Kinetics Asset Management LLC

Horizon Kinetics Asset Management LLC lessened its stake in Bicycle Therapeutics plc (NASDAQ:BCYC) by 4.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,792 shares of the company’s stock after selling 604 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Bicycle Therapeutics were worth $312,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Assetmark Inc. acquired a new stake in Bicycle Therapeutics during the third quarter worth $34,000. GAMMA Investing LLC increased its stake in Bicycle Therapeutics by 105.1% during the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after acquiring an additional 2,918 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Bicycle Therapeutics during the second quarter worth $206,000. Finally, Crossmark Global Holdings Inc. purchased a new position in shares of Bicycle Therapeutics during the third quarter worth $257,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Trading Up 2.3 %

NASDAQ:BCYC opened at $20.40 on Wednesday. The firm has a market cap of $970.02 million, a PE ratio of -6.18 and a beta of 0.89. The stock has a fifty day moving average price of $23.87 and a 200 day moving average price of $23.01. Bicycle Therapeutics plc has a 12-month low of $13.31 and a 12-month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Bicycle Therapeutics’s revenue for the quarter was down 50.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.26) EPS. Equities analysts forecast that Bicycle Therapeutics plc will post -3.07 EPS for the current year.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the sale, the chief executive officer now directly owns 380,864 shares of the company’s stock, valued at $8,478,032.64. The trade was a 0.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.16. Following the sale, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,840 shares of company stock valued at $259,128 in the last ninety days. Insiders own 8.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on BCYC shares. JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Stephens started coverage on Bicycle Therapeutics in a research report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price target for the company. B. Riley lowered Bicycle Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $33.00 to $28.00 in a research report on Wednesday, August 7th. Finally, Oppenheimer restated an “outperform” rating and set a $48.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.13.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.